Wikimedia CommonsPfizer Inc. (NYSE: PFE) reported third-quarter 2013 results before markets opened Tuesday morning. The drug maker posted adjusted diluted earnings per share (EPS) of $0.58 and revenues of $12.64 billion. In the same…
The drug patent cliff for Big Pharma is coming with some continued consequences, and two drug giants with earnings this week are Dow Jones Industrial Average components. Merck & Co. (NYSE: MRK) reported earnings on…
Healthcare.govSince the passage of the Affordable Care Act, or Obamacare, the launch has been riddled with problems. Accessing the sign-up page, poor Web design, untested and inept technology, and endless attacks on how the…
ThinkstockDrug giant Merck & Co. Inc. (NYSE: MRK) reported third-quarter 2013 results before markets opened Monday morning. The company posted adjusted diluted earnings per share (EPS) of $0.92 and revenues of $11.03 billion. In…
ThinkstockIt is not uncommon that a loss of business at one provider is a win for other providers. If you have followed the Healthcare.gov list of continual sign-up issues since the start of the…
ThinkstockBiotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can lose it all if they…
ThinkstockUnitedHealth Group Inc. (NYSE: UNH) reported third-quarter 2013 results before markets opened Thursday morning. The health insurance and benefits management firm posted diluted quarterly earnings per share (EPS) of $1.53 on revenues of $30.6…
ThinkstockBiotech is a sector where investors know they are entering a high-stakes game of big risk and big reward. That is particularly the case for the small-cap biotech stocks that have no products and…
ThinkstockSome good news for makers of cookies and candy. Recent research shows that Oreos are as addictive as cocaine. However, the companies may want to hold off celebrating. The data are based on the habits of…
Wikimedia CommonsJohnson & Johnson (NYSE: JNJ) reported third-quarter 2013 results before markets opened Tuesday morning. The health care giant posted quarterly adjusted diluted earnings per share (EPS) of $1.36 on revenue of $17.58 billion.…
ThinkstockIf you have followed the diabetes drug market for very long, chances are high that you have run across the possibility of an inhalable form of insulin ultimately being approved by the Food &…
Investing in biotech and emerging pharmaceutical stocks comes with a huge risk and reward profile for investors. Some wins are exponential, yet some losses are losses of the entire investment. Coronado Biosciences Inc. (NASDAQ:…
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated does. That…
Thinkstock What’s Missing — October 21, 2013 The implementation of the health insurance exchanges that began on October 1 has not been an unqualified success. The Congressional Budget Office estimates for the costs of…
via Wikimedia CommonsAriad Pharmaceuticals Inc. (NASDAQ: ARIA) is getting crushed on Wednesday due to a clinical hold placed by the U.S. Food & Drug Administration. The company confirmed that the FDA has placed a…